Papaverine

Phase 1Small molecule

Papaverine is one of 18 small molecule programs targeting Locally Advanced Lung Non-Small Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Lung Non-Small Cell CarcinomaRecruiting

Locally Advanced Rectal AdenocarcinomaRecruiting

Locally Advanced Lung Non-Small Cell CarcinomaPhase 1

Recruiting

Locally Advanced Rectal AdenocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Locally Advanced Lung Non-Small Cell Carcinoma

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

2 2

Taxol

Teva

Phase 3

2 3

Abraxane

Bristol-Myers Squibb

Phase 3

1 4

Tagrisso

AstraZeneca

Phase 3

1 5

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

2 6

Alimta

SShawn Eagle

Phase 3

2 7

Paraplatin

AAvyxa

Phase 3

2 8

Vepesid

AAvyxa

Phase 3

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 10

Avastin

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Locally Advanced Lung Non-Small Cell Carcinoma

NCT05136846

Q2 2027

PreclinicalRecruiting

Premature Rupture of Fetal Membranes

NCT07826533

Q3 2028

Phase 1Recruiting

Locally Advanced Rectal Adenocarcinoma

NCT06834126

Clinical

Trials by Indication[1]

Labor Induction2 trials

Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction

Not yet recruiting·WWestern Galilee Hospital-Nahariya·N/A·NCT06547437·126 enrolled

IV PAPAVERINE Prior to Propess for Labor Induction

Completed·WWestern Galilee Hospital-Nahariya·Phase 4·NCT06550232·110 enrolled

Pediatric Patients1 trial

Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03894904·100 enrolled

Gastroenteritis1 trial

Optimal Analgesia in Acute Gastroenteritis

Terminated·HHadassah Medical Organization·Phase 3·NCT02711241·15 enrolled

Volume1 trial

Effect of Papaverine on Renal Artery Blood Flow Volume

Completed·—·Phase 4·NCT04162834·96 enrolled

ART1 trial

The Effect of Periradial Injection of Papaverine Versus Nitroglycerine on Radial Artery Diameter

Completed·KKasr El Aini Hospital·Phase 1·NCT04030663·90 enrolled

5 more indications

Hyperplasia1 trial

Prostatic Hyperplasia Treatment and Cancer Prevention

Unknown status·MManchanda Medical Clinic·Phase 1·NCT03064282·40 enrolled

Erectile Dysfunction1 trial

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00080808·111 enrolled

Premature Rupture of Fetal Membranes1 trial

The Effect of Papaverine on Labour in Term Premature Rupture of Membranes (PROM)

Recruiting·WWolfson Medical Center·Preclinical·NCT07826533·200 enrolled

Locally Advanced Rectal Adenocarcinoma1 trial

DINOMITE (Decreasing Hypoxia With Mitochondrial Inhibition in Locally Advanced Rectal Cancer): Phase 1 Trial of Papaverine in Combination With Radiation

Recruiting·CCity of Hope Medical Center·Phase 1·NCT06834126·36 enrolled

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05136846·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Papaverine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Papaverine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Papaverine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Western Galilee Hospital-Nahariya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWestern Galilee Hospital-Nahariya

Papaverine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2028

Trials by Indication[1]

Labor Induction2 trials

Pediatric Patients1 trial

Gastroenteritis1 trial

Volume1 trial

ART1 trial

Hyperplasia1 trial

Erectile Dysfunction1 trial

Premature Rupture of Fetal Membranes1 trial

Locally Advanced Rectal Adenocarcinoma1 trial

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News